Biogen vs Mettler-Toledo International

Biogen (BIIB), health care, and Mettler-Toledo International (MTD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Biogen is worth $37.1B on the stock market and Mettler-Toledo International $34.1B: Biogen is valued at 9% more. Biogen trades at 109 times earnings and Mettler-Toledo International at 37.5. Over the past year Biogen's share price has moved +49.1% and Mettler-Toledo International's +23.7%.

Key facts

Biogen market value
$37.1B
Mettler-Toledo International market value
$34.1B
Biogen P/E
109
Mettler-Toledo International P/E
37.5
Biogen revenue
$9.9BFY to 2025-12-31
Mettler-Toledo International revenue
$4BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Biogen vs Mettler-Toledo International: every measure side by side
Measure Biogen Mettler-Toledo International
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$37.1Bhigher$34.1Blower
Revenue$9.9Bhigher$4Blower
Earnings$1.3Bhigher$869.2Mlower
Employees7,500lower16,600higher
Total assets$29.4Bhigher$3.7Blower
Valuation
P/E109higher37.5lower
P/S3.7lower8.5higher
P/B2.0lower439higher
Dividend yield0.00%0.00%
Profitability
Operating margin——
Balance sheet
Net assets$18.3Bhigher-$23.6Mlower
Total liabilities$11.2Bhigher$3.7Blower
Total debt$6.3Bhigher$2.2Blower
Cash on hand$3Bhigher$66.9Mlower
Price change
Today-0.34%higher-0.83%lower
1 year+49.1%higher+23.7%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Mettler-Toledo International only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns BIIB · Who owns MTD

Further comparisons

Learn

Questions and answers

Which is bigger, Biogen or Mettler-Toledo International?

By market value, Biogen is the larger: $37.1B against $34.1B for Mettler-Toledo International. By revenue in its latest fiscal year, Biogen is the larger: $9.9B against $4B for Mettler-Toledo International.

Which has the higher P/E ratio?

Biogen: 109, against 37.5 for Mettler-Toledo International. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Biogen: $6.3B, against $2.2B for Mettler-Toledo International. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Biogen and Mettler-Toledo International?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Biogen and 3 hold Mettler-Toledo International.

Cite this page

Funkfolio, “Biogen vs Mettler-Toledo International”, data as of 18 November 2026. https://funkfolio.com/compare/biib-vs-mtd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.